DrugPatentWatch Database Preview
Eyevance Company Profile
What is the competitive landscape for EYEVANCE, and when can generic versions of EYEVANCE drugs launch?
EYEVANCE has two approved drugs.
There are four US patents protecting EYEVANCE drugs.
There are fifteen patent family members on EYEVANCE drugs in five countries and two supplementary protection certificates in two countries.
Summary for Eyevance
| International Patents: | 15 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Eyevance
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | 9,254,286*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | 9,750,684 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | 8,829,005*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Eyevance Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2015007136 | ➤ Sign Up |
| Japan | 2013522312 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2011116020 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2010107689 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for Eyevance Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0663828 | C300085 | Netherlands | ➤ Sign Up | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| 0058146 | 2001C/045 | Belgium | ➤ Sign Up | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
